- Record: found
- Abstract: found
- Article: not found
Efficacy and safety of argatroban and bivalirudine in patients with suspected heparin-induced thrombocytopenia.
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Argatroban is the only commercially available Food and Drug Administration (FDA)-approved anticoagulant for managing heparin-induced thrombocytopenia (HIT). However, bivalirudin may be an attractive alternative.